Structure via PubChem · Public domain (PubChem)
A-86929
Sign in to saveAlso known as (5aR,11bS)-2-propyl-4,5,5a,6,7,11b-hexahydrobenzo[f]thieno[2,3-c]quinoline-9,10-diol
A-86929 is a synthetic compound that acts as a selective dopamine receptor D1 agonist. It was developed as a possible treatment for Parkinson's disease, as well as for other applications such as treatment of cocaine addiction, but while it had reasonable efficacy in humans it also caused dyskinesias and has not been continued. It has mainly been used as its diacetate ester prodrug adrogolide (A-93431; ABT-431; DAS-431), which has better pharmacokinetics.
Chemical data
- Formula
- C18H21NO2S
- Molecular weight
- 315.4 g/mol
- IUPAC name
- (1S,10R)-15-propyl-14-thia-11-azatetracyclo[8.7.0.02,7.013,17]heptadeca-2,4,6,13(17),15-pentaene-4,5-diol
- SMILES
- CCCC1=CC2=C(S1)CN[C@H]3[C@H]2C4=CC(=C(C=C4CC3)O)O
- InChIKey
- REHAKLRYABHSQJ-KDOFPFPSSA-N
- XLogP
- 3.4
- Polar surface area
- 80.7 Ų
- H-bond donors
- 3
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Molecule type
- Small molecule
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 315.1293
Show 3 more facts
- chemical formula
- C₁₈H₂₁NO₂S
- isomeric SMILES
- CCCC1=CC2=C(S1)CN[C@H]3[C@H]2C4=CC(=C(C=C4CC3)O)O
- canonical SMILES
- CCCC1=CC2=C(S1)CNC3C2C4=CC(=C(C=C4CC3)O)O
Sources (1)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
A-86929 is a synthetic compound that acts as a selective dopamine receptor D1 agonist. It was developed as a possible treatment for Parkinson's disease, as well as for other applications such as treatment of cocaine addiction, but while it had reasonable efficacy in humans it also caused dyskinesias and has not been continued. It has mainly been used as its diacetate ester prodrug adrogolide (A-93431; ABT-431; DAS-431), which has better pharmacokinetics.
160px|thumb|left|class=skin-invert-image|Adrogolide.
Excerpted from Wikipedia’s “A-86929” article, available under the CC BY-SA 4.0 licence.